Eli Lilly And Co (LLY) Position Lifted by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC increased its position in shares of Eli Lilly And Co (NYSE:LLY) by 13.7% during the 3rd quarter, Holdings Channel reports. The fund owned 4,902 shares of the company’s stock after buying an additional 591 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Eli Lilly And Co were worth $527,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Gyroscope Capital Management Group LLC raised its holdings in shares of Eli Lilly And Co by 0.5% in the third quarter. Gyroscope Capital Management Group LLC now owns 89,849 shares of the company’s stock valued at $10,334,000 after purchasing an additional 469 shares during the last quarter. Bbva Compass Bancshares Inc. raised its holdings in shares of Eli Lilly And Co by 5.3% in the third quarter. Bbva Compass Bancshares Inc. now owns 9,349 shares of the company’s stock valued at $1,003,000 after purchasing an additional 474 shares during the last quarter. Pure Financial Advisors Inc. raised its holdings in shares of Eli Lilly And Co by 18.3% in the third quarter. Pure Financial Advisors Inc. now owns 3,166 shares of the company’s stock valued at $340,000 after purchasing an additional 490 shares during the last quarter. Balasa Dinverno & Foltz LLC raised its holdings in shares of Eli Lilly And Co by 15.9% in the third quarter. Balasa Dinverno & Foltz LLC now owns 3,629 shares of the company’s stock valued at $389,000 after purchasing an additional 499 shares during the last quarter. Finally, Legacy Private Trust Co. raised its holdings in shares of Eli Lilly And Co by 5.2% in the third quarter. Legacy Private Trust Co. now owns 10,365 shares of the company’s stock valued at $1,112,000 after purchasing an additional 508 shares during the last quarter. 76.17% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have recently issued reports on LLY shares. BMO Capital Markets lifted their price objective on shares of Eli Lilly And Co from $78.00 to $80.00 and gave the company a “$89.43” rating in a report on Thursday, July 19th. TheStreet upgraded shares of Eli Lilly And Co from a “c+” rating to a “b+” rating in a report on Tuesday. Cowen set a $105.00 price objective on shares of Eli Lilly And Co and gave the company a “buy” rating in a report on Tuesday, July 24th. Cantor Fitzgerald set a $100.00 price objective on shares of Eli Lilly And Co and gave the company a “buy” rating in a report on Tuesday, July 24th. Finally, Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Wednesday, July 18th. Nine investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $111.19.

In related news, SVP Alfonso G. Zulueta sold 6,000 shares of the business’s stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $106.31, for a total transaction of $637,860.00. Following the transaction, the senior vice president now directly owns 55,224 shares in the company, valued at $5,870,863.44. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Eli & Co Lilly sold 700,000 shares of the business’s stock in a transaction on Tuesday, November 6th. The stock was sold at an average price of $14.00, for a total transaction of $9,800,000.00. Following the transaction, the insider now owns 3,148,647 shares in the company, valued at $44,081,058. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,881,684 shares of company stock worth $133,274,076. 0.11% of the stock is owned by corporate insiders.

Shares of LLY opened at $112.21 on Friday. The firm has a market cap of $116.23 billion, a P/E ratio of 20.43, a PEG ratio of 1.75 and a beta of 0.29. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $116.61. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.09 and a current ratio of 1.91.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. The business had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.05 earnings per share. On average, analysts predict that Eli Lilly And Co will post 5.57 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Investors of record on Thursday, November 15th will be issued a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.01%. Eli Lilly And Co’s payout ratio is 52.57%.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://sportsperspectives.com/2018/11/10/eli-lilly-and-co-lly-position-lifted-by-chicago-partners-investment-group-llc.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: How can you know how many shares are floating?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply